Co-Diagnostics, Inc. Sustainability Profile
Co-Diagnostics, Inc., a leading biotechnology firm headquartered in the United States, specialises in molecular diagnostics and innovative testing solutions. Founded in 2013, the company has made significant strides in the industry, particularly with its proprietary CoPrimer technology, which enhances the accuracy and efficiency of diagnostic tests. With a focus on infectious diseases, including COVID-19, Co-Diagnostics has developed a range of unique products that stand out for their reliability and rapid results. The company operates primarily in North America and has expanded its reach globally, establishing a strong market position through strategic partnerships and a commitment to quality. Notable achievements include the successful launch of multiple diagnostic tests that have garnered regulatory approvals, solidifying Co-Diagnostics' reputation as a pioneer in the molecular diagnostics sector.
DitchCarbon Score
How does Co-Diagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Co-Diagnostics, Inc.'s score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Co-Diagnostics, Inc.'s reported carbon emissions
Co-Diagnostics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in their latest emissions report. Consequently, there are no recorded Scope 1, Scope 2, or Scope 3 emissions totals available for analysis. Additionally, Co-Diagnostics has not established any documented reduction targets or commitments to climate initiatives, which further highlights the lack of formal climate action strategies at this time. Without emissions data or reduction initiatives, it is challenging to assess their environmental impact or commitment to sustainability. As the company operates within an industry increasingly focused on climate responsibility, it may benefit from developing clear emissions reporting and reduction strategies to align with global climate goals and stakeholder expectations.
How Carbon Intensive is Co-Diagnostics, Inc.'s Industry?
How Carbon Intensive is Co-Diagnostics, Inc.'s Location?
Co-Diagnostics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Co-Diagnostics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
